deltatrials
Terminated PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT03068754

Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)

A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis

Sponsor: Mallinckrodt

Interventions Acthar Placebo
Updated 21 times since 2017 Last updated: Sep 18, 2020 Started: Jun 22, 2017 Primary completion: Nov 25, 2019 Completion: Nov 25, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

As recommended by the study's independent Data and Safety Monitoring Board (DSMB)

This PHASE2/PHASE3 trial investigates Amyotrophic Lateral Sclerosis and is currently terminated or withdrawn. Mallinckrodt leads this study, which shows 21 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2017 – ~Jul 2017 · 4 months · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Apr 2018 · 6 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jul 2019 · 7 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Nov 2019 · 3 months · monthly snapshot~Nov 2019 – ~Oct 2020 · 11 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

21 versions recorded
  1. Nov 2025 — Present [monthly]

    Terminated PHASE2/PHASE3

  2. Sep 2025 — Nov 2025 [monthly]

    Terminated PHASE2/PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2/PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2/PHASE3

    Phase: PHASE2_PHASE3PHASE2/PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2_PHASE3

Show 16 earlier versions
  1. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE2_PHASE3

  2. Oct 2020 — Nov 2020 [monthly]

    Terminated PHASE2_PHASE3

  3. Nov 2019 — Oct 2020 [monthly]

    Terminated PHASE2_PHASE3

    Status: Active Not RecruitingTerminated

  4. Aug 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: RecruitingActive Not Recruiting

  5. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2_PHASE3

    Phase: PHASE2PHASE2_PHASE3

  6. Dec 2018 — Jul 2019 [monthly]

    Recruiting PHASE2

  7. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  8. Sep 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  9. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  10. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  11. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  12. Oct 2017 — Apr 2018 [monthly]

    Recruiting PHASE2

  13. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  14. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  15. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  16. Mar 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mallinckrodt
Data source: Mallinckrodt

For direct contact, visit the study record on ClinicalTrials.gov .